跳至主要内容
临床试验/JPRN-jRCT2071210138
JPRN-jRCT2071210138已完成1 期

To compare the Pharmacokinetics (PK) / Pharmacodynamics(PD)of a single subcutaneous (sc) injection (3.6 mg) of MYL-1401H and G-Lasta in Japanese healthy adult volunteers

Koichi Iwai0 个研究点目标入组 171 人开始时间: 2022年3月26日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
171

研究概览

简要总结

The study demonstrated bioequivalence between MYL-1401H and G-Lasta based on the primary PK and PD parameters. Additionally, both products had similar safety and tolerability profile after the single administration

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 55age old(—)
性别
All

入选标准

  • A subject will be eligible at the screening visit (unless otherwise stated) if all of the Protocol apply
  • 1 Willingness and ability to provide informed consent.
  • 2 Japanese male and/or female
  • 3 Age: 20-55 years, inclusive.
  • 4 Weight: >45 kg.
  • In addition, follow the criteria of the clinical trial protocol

排除标准

  • A subject will be not be eligible at the screening visit (unless otherwise stated) if any of the Protocol apply
  • 1 Unable to follow protocol instructions in the opinion of the PI/SI.
  • 2 Any past or concurrent medical conditions that potentially increase the subjects risks or affect the evaluation of any study results. Examples of these include medical history with evidence of clinically relevant pathology (e.g., sickle cell disorders,spleen pathologies, hematologic malignancies or myelodysplastic disorders, and pulmonary illnesses such as acute respiratory distress syndrome (ARDS), interstitial pneumonia, pulmonary edema, pulmonary infiltrates and pulmonary fibrosis) and history of relevant drug and/or food allergies.

研究者

发起方
Koichi Iwai

相似试验